Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
Ximeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
C Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Immunology Research
|
March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancer
Emily Bontekoe, Minying Zhang, Peixin Jiang, et al.
JTO Clinical and Research Reports
|
February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic Targets
Bingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Biomolecules
|
November 11, 2022
Replicative Instability Drives Cancer Progression
Benjamin B Morris, Jason P Smith, Qi Zhang, et al.
Cancer Cell
|
January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
Simon Heeke, Carl M Gay, Marcos R Estecio, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
Ximeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
C Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Immunology Research
|
March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancer
Emily Bontekoe, Minying Zhang, Peixin Jiang, et al.
JTO Clinical and Research Reports
|
February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic Targets
Bingnan Zhang, Whitney Lewis, C Allison Stewart, et al.
Biomolecules
|
November 11, 2022
Replicative Instability Drives Cancer Progression
Benjamin B Morris, Jason P Smith, Qi Zhang, et al.
Cancer Cell
|
January 26, 2024
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
Simon Heeke, Carl M Gay, Marcos R Estecio, et al.
Page
of 2